TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25042797
Drug: Peginterferon lambda-1a
Normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon lambda-1a (Lambda) at all doses with ribavirin
Study: 25043069
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg loading dose (LD)
Study: 25043069
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg maintenance dose (MD)
Study: 25043069
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg loading dose (LD) in CYP2C19 loss-of-function carriers
Study: 25043069
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg maintenance dose (MD) in CYP2C19 loss-of-function carriers
Study: 25043069
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg loading dose (LD) in CYP2C19 non-carriers
Study: 25043069
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg maintenance dose (MD) in CYP2C19 non-carriers
Study: 25043869
Drug: suPAR levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: suPAR levels in patient groups (initial level 18.8 ng/mL, range 6.8-30.1 ng/mL)
Study: 25043869
Drug: suPAR levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: suPAR levels in control group (initial level 6.0 ng/mL, range 3.7-10.8 ng/mL)
Study: 25046246
Drug: Combined pharmacotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined pharmacotherapy and psychotherapy (cognitive behavioral therapy or psychoeducation)
Study: 25047123
Drug: Lenvatinib (E7080)
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib (E7080) administered twice daily in 3-week cycles; 2 weeks of treatment followed by 1 week of rest.
Study: 25047747
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy plus bevacizumab
Study: 25047979
Drug: Pomalidomide (0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide (0.5mg daily) with prednisone (for the first 3 cycles)
Study: 25049247
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg posaconazole once daily
Study: 25049247
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg posaconazole once daily
Study: 25049249
Drug: Artemisinin (ART)-based
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin (ART)-based combination therapies (ACTs)
Study: 25052051
Drug: Obatoclax mesylate
Normalized name: mesylate
DrugBank: Obatoclax (DB12191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obatoclax mesylate 60 mg intravenous over 24 hours every 2 weeks
Study: 25052451
Drug: Gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,000 mg/m² on days 1 and 8 and cisplatin 70 mg/m² on day 1 every 21 days with lenalidomide 10 mg daily on days 1-14 (phase Ib).
Study: 25052451
Drug: Gemcitabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and cisplatin (GCL) regimen without lenalidomide (control group not explicitly mentioned but implied as standard treatment).
Study: 25052720
Drug: IMRT-HT (Intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT-HT (Intensity Modulated Radiation Therapy delivered by helical tomotherapy)
Study: 25056691
Drug: Essential amino
Normalized name: Essential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential amino acids (EAAs) ingestion (13 g; 2.4 g of Leu)
Study: 25057177
Drug: Temsirolimus 25
Normalized name: temsirolimus 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus 25 mg i.v. weekly added to rituximab (375 mg/m2 i.v. day 1) and cladribine (5 mg/m2/day i.v. days 1-5 of a 28-day cycle)
Study: 25057177
Drug: Temsirolimus 25
Normalized name: temsirolimus 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus 25 mg i.v. weekly added to rituximab and cladribine
Study: 25057265
Drug: Nonselective nonsteroidal
Normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs)
Study: 25057276
Drug: pterostilbene 125 mg
DrugBank: Pterostilbene (DB17939)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pterostilbene 125 mg twice daily
Study: 25057276
Drug: pterostilbene 50 mg
DrugBank: Pterostilbene (DB17939)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pterostilbene 50 mg twice daily
Study: 25057276
Drug: pterostilbene 50 mg
DrugBank: Pterostilbene (DB17939)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pterostilbene 50 mg + grape extract (GE) 100 mg twice daily
Study: 25057276
Drug: high dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose pterostilbene
Study: 25058217
Drug: Nonmyeloablative allogeneic
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmyeloablative allogeneic hematopoietic stem cell transplantation (HSCT) with alemtuzumab (1 mg/kg), total-body irradiation (300 cGy), sirolimus, and filgrastim mobilized peripheral blood stem cells (5.5-31.7 × 10(6) cells/kg)
Study: 25058267
Drug: Peritoneal lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritoneal lactate value greater than 9.1 mmol/L
Study: 25062507
Drug: Dextromethorphan/quinidine (DM/Q)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan/quinidine (DM/Q) 30/30 mg twice daily
Study: 25062770
Drug: Decitabine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decitabine 0.1 or 0.2 mg/kg three times weekly for 2 weeks, Panobinostat 10, 20, or 30 mg every 96 h, Temozolomide 150 mg/m(2)/day on days 9-13 (increased to 200 mg/m(2)/day in cycle 2 if no neutropenia or thrombocytopenia)
Study: 25062770
Drug: Maintenance protocol
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance protocol with weekly panobinostat and thrice-weekly decitabine until tumor progression, unacceptable toxicity, or withdrawal of consent
Study: 25064094
Drug: Pirfenidone (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirfenidone (1200 mg/day) for 24 months
Study: 25067985
Drug: Cactus fiber
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cactus fiber (2 tablets thrice daily with main meals)
Study: 25067985
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 tablets thrice daily with main meals)
Study: 25069627
Drug: Opioids and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioids and/or acetaminophen (oral oxycodone and/or acetaminophen)
Study: 25069627
Drug: Opioids (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioids (total daily consumption)
Study: 25069627
Drug: Analgesic administration
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic administration methods
Study: 25070153
Drug: Oral nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nicorandil (15 mg/d, nicorandil group)
Study: 25070153
Drug: Oral nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nicorandil
Study: 25074036
Drug: Gemcitabine (800-1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (800-1,000 mg/m² on days 1, 8, and 15, then every 3-4 weeks)
Study: 25074036
Drug: S-1 (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (40-80 mg/m²/day on days 1-28, then every 3-6 weeks)
Study: 25075006
Drug: Fondaparinux with
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fondaparinux with unfractionated heparin (UFH)
Study: 25075128
Drug: Afuresertib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afuresertib (125 mg per day, maximum tolerated dose)
Study: 25075128
Drug: Afuresertib (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afuresertib (doses ranging from 25 to 150 mg per day)
Study: 25075128
Drug: Afuresertib (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afuresertib (doses > 75 mg)
Study: 31634044
Drug: MenACWY-CRM vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-CRM vaccine
Study: 25075833
Drug: KAE609 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAE609 (30 mg per day for 3 days)
Study: 25075833
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate (not specified dosage or duration)
Study: 25076364
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of 0.5 mL of bevacizumab (2.5 mg/0.1 mL)
Study: 25076495
Drug: Diets emphasizing
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diets emphasizing tree nuts (median dose of 56 g/d)
Study: 25077099
Drug: Immediate-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release morphine sulfate syrup (initially 0.5 mg twice daily, titrated based on weekly assessments)
Study: 25077099
Drug: Immediate-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release morphine sulfate syrup
Study: 25077107
Drug: Sufficient vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufficient vitamin D levels (≥ 75 nmol/L)
Study: 25077107
Drug: Insufficient vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insufficient vitamin D levels (< 75 nmol/L)
Study: 25079400
Drug: Intensive oral
Normalized name: Uricalm Intensive Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive oral hygiene regimen with oral hygiene products and non-surgical therapy
Study: 25079400
Drug: Intensive oral
Normalized name: Uricalm Intensive Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive oral hygiene regimen
Study: 25080050
Drug: Isolated raised
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated raised base excess (BE) (≥ 2 mmol/L)
Study: 25080540
Drug: Iron deficiency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron deficiency (sTfR > 8.5 mg/L)
Study: 25084608
Drug: Proton beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton beam radiation therapy to the surgical bed, 40 Gy in 10 fractions, once daily over 2 weeks.
Study: 25085632
Drug: Sunitinib (Sutent)
Normalized name: sunitinib Oral Capsule [Sutent]
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib (Sutent) - a VEGFR2/PDGFRβ/c-kit/FLT3/RET/CSF1R inhibitor
Study: 25086465
Drug: Imatinib, dacarbazine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib, dacarbazine, and capecitabine regimen (imatinib 300 mg daily on days 1-21, dacarbazine 250 mg/m2 daily on days 1-3, capecitabine 500 mg/m2 twice daily on days 1-14)
Study: 25086913
Drug: Metformin (61.2%)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (61.2%)
Study: 25086913
Drug: Insulin (18%)
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin (18%)
Study: 25090645
Drug: AS03A-H5N1 vaccine
Normalized name: influenza A virus (H5N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03A-H5N1 vaccine (3.75μg hemagglutinin-antigen)
Study: 25091263
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg/day on days 2-5, 9-12, 16-26 of each 28-day cycle plus gemcitabine 1000 mg/m(2) as an intravenous infusion over 30-min on days 1, 8, 15
Study: 25091537
Drug: Aztreonam for
Normalized name: Aztreonam for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam for inhalation solution (AZLI) 75 mg 3 times daily for 28 days
Study: 25091619
Drug: Ixabepilone 40
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone 40 mg/m² on day one of a 21 day cycle
Study: 25093475
Drug: Brief pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief pulse right unilateral electroconvulsive therapy (ECT)
Study: 25093475
Drug: Ultrabrief pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrabrief pulse right unilateral electroconvulsive therapy (ECT)
Study: 25099027
Drug: TACE/sorafenib combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE/sorafenib combination
Study: 25101571
Drug: Nitinol stent
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitinol stent treatment
Study: 25102383
Drug: Cumulative Illness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative Illness Rating Scale-Geriatric (CIRS-G)
Study: 25105369
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy with O6BG/TMZ chemotherapy
Study: 25105369
Drug: Historical controls
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical controls without gene therapy
Study: 25110632
Drug: 7.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg single dose
Study: 25110632
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg single dose
Study: 25110632
Drug: 7.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg two doses
Study: 25110632
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg two doses
Study: 25111234
Drug: Azithromycin treatment
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin treatment (median duration 4 days, range 2-7 days)
Study: 25112732
Drug: Recombinant LCN2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant LCN2 treatment
Study: 25113756
Drug: LCL161 (1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCL161 (1,800 mg, oral, once weekly, tablet formulation)
Study: 25113756
Drug: LCL161 (tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCL161 (tablet formulation)
Study: 25113756
Drug: LCL161 (1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCL161 (1,800 mg)
Study: 25114718
Drug: anti-HER2 agents
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: anti-HER2 agents
Study: 25115686
Drug: Resveratrol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (1 gm daily for 12 weeks)
Study: 25116755
Drug: Cyclophosphamide, GM-CSF-secreting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide, GM-CSF-secreting breast tumor vaccine, and trastuzumab
Study: 25117475
Drug: Cabazitaxel/cisplatin (15/75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel/cisplatin (15/75 mg/m²)
Study: 25117475
Drug: Cabazitaxel/cisplatin (20/75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel/cisplatin (20/75 mg/m²)
Study: 25117615
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (AA) 1000 mg (1 h premeal)
Study: 25117615
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (AA) 1000 mg (2 h postmeal)
Study: 25119513
Drug: Patient-therapist working
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-therapist working alliance and patient expectations of treatment benefit
Study: 25122609
Drug: ABC294640 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABC294640 (a SK2 specific inhibitor)
Study: 25122609
Drug: ABC294640 +
Normalized name: ABC294640
DrugBank: Opaganib (DB12764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABC294640 + ABT-737 (a Bcl-2 inhibitor)
Study: 25123851
Drug: Testosterone 2%
Normalized name: TESTOSTERONE 2% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone 2% solution (Axiron®), 60-mg daily morning dose applied to axillae (30 mg/axilla)
Study: 25125727
Drug: LV end-diastolic
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LV end-diastolic volume > 98 mL/m(2)
Study: 25125727
Drug: Creatinine level
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatinine level > 1.49 mg/dL
Study: 25125727
Drug: No angiotensin-inhibition
Approvals — FDA: no, EMA: no, PMDA: no
Description: No angiotensin-inhibition therapy
Study: 25125727
Drug: Absence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absence of all four factors (denervated myocardium, LV end-diastolic volume, creatinine level, angiotensin-inhibition therapy)
Study: 25125727
Drug: Two or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two or more factors (denervated myocardium, LV end-diastolic volume, creatinine level, angiotensin-inhibition therapy)
Study: 25126443
Drug: Intrathecal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of autologous bone marrow mononuclear cells (BMMNCs)
Study: 25126880
Drug: Lactate level
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate level more than 1.5 mEq/L
Study: 25127916
Drug: Steroid regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid regimen with median dosing of 55 mg/m2/day, median cumulative dose of 3,440 mg/m2 for the first episode, median duration of 21 weeks.
Study: 25127916
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment including albumin infusions, diuretics, and acetyl salicylic acid.
Study: 25129345
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m² every 3 weeks for four cycles
Study: 25130947
Drug: 88 μg·kg(-1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 88 μg·kg(-1) of epinephrine (1:10,000) injected into the caudal epidural space
Study: 25132507
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg vaccine
Study: 25132507
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg vaccine
Study: 25132507
Drug: 40 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 μg vaccine
Study: 25133198
Drug: Rifaximin 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 1.2 g/day for 15 days/month for 2 months
Study: 25133431
Drug: Anakinra 100
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg subcutaneously for 84 days
Study: 25135035
Drug: Pregabalin (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (100, 150, 300, or 600 mg/day)
Study: 25135992
Drug: R2CHOP (lenalidomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: R2CHOP (lenalidomide 25 mg orally per day on days 1-10 combined with standard-dose R-CHOP every 21 days for six cycles)
Study: 25136536
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g Korean white ginseng (KWG)
Study: 25136689
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid injections (5 weekly injections)
Study: 25137424
Drug: Endometriosis lesions
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometriosis lesions with contraceptive medication
Study: 25137427
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy leading to remission (normal IGF-1)
Study: 25139963
Drug: Telaprevir (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telaprevir (750 mg or 1125 mg every 8 hours with efavirenz) plus peg-IFN alfa-2a (180 µg/week) and RBV (1000-1200 mg/day) for 12 weeks followed by peg-IFN/RBV for 32-56 weeks according to virological response at week 8
Study: 25141112
Drug: Ringer's acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's acetate (1470 ml) and mannitol (15% 200 ml) during cardiopulmonary bypass
Study: 25142258
Drug: SGN-75 administered
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SGN-75 administered Q3Wk at doses escalated from 0.3 to 4.5 mg/kg
Study: 25142258
Drug: SGN-75 administered
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SGN-75 administered weekly at doses of 0.3 or 0.6 mg/kg
Study: 25142258
Drug: SGN-75 administered
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SGN-75 administered Q3Wk
Study: 25142258
Drug: SGN-75 treatment
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGN-75 treatment
Study: 25142258
Drug: SGN-75 administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGN-75 administration Q3Wk vs. weekly dosing
Study: 25142486
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard ICS treatment)
Study: 25142735
Drug: PF-04937319 (glucokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04937319 (glucokinase activator) at doses of 100 mg and 300 mg
Study: 25143232
Drug: Multiplex method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiplex method using Luminex technology to detect antibodies against 32 synthetic biotinylated peptides comprising predicted neo-antigens.
Study: 25143374
Drug: 22-element multiple
Normalized name: Calcium, elemental
DrugBank: Calcium (DB01373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22-element multiple micronutrient powder (MNP) administered daily for 5 months
Study: 25143487
Drug: Obinutuzumab 400
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab 400 to 1200 mg (phase 1)
Study: 25143487
Drug: Obinutuzumab 1000
Normalized name: obinutuzumab 1000 MG in 40 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obinutuzumab 1000 mg (phase 2)
Study: 25145344
Drug: BFR regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFR regimen (bendamustine 130 mg/m2 per day for 3 days, fludarabine, and rituximab)